VERACITY®

new generation NIPT



Delivering results you can trust

MEDICOVER GENETICS

VERACITY NEW GENERATION NIPT

VERACITY is a **non-invasive prenatal test (NIPT)** that can accurately detect the presence of certain foetal genetic disorders as early as the **9th week** of pregnancy, through a blood sample from the pregnant woman.

- Applicable for women of **all ages**
- Validated for **singleton** and **twin** pregnancies
- Applicable for **IVF** pregnancies
- Preferred for its **clinical performance**

WHAT IS A PRENATAL TEST?

Prenatal test is a test that a pregnant woman can take to check if her foetus has certain genetic conditions. Prenatal tests are divided into **screening** and **diagnostic**, which **work synergistically**.

The more accurate a screening test is, the fewer women are being referred for diagnostic testing.

Clinical Results that Matter

WHY SHOULD I CONSIDER NIPT?

Every pregnancy carries a chance of chromosomal abnormalities, regardless of maternal age or family history. NIPT is the most accurate non-invasive screening test available for common chromosomal conditions, including Down syndrome[1,2]. With a simple blood test, it provides reliable information about your baby's risk and can help support informed decisions about your pregnancy care.

Because of its high accuracy, NIPT reduces the likelihood of false-positive results and may help avoid unnecessary invasive procedures such as amniocentesis or CVS.


Additionally, certain genetic conditions, such as **sex chromosome aneuploidies** and **selected microdeletions**, are **not always associated with maternal age** and may not be detected through traditional biochemical screening.

1. *ACOG Committe on Practice Bulletins."Screening for Fetal Chromosomal Abnormalities." Obstetrics & Gynecology, vol. 136, no. 4, 2020, https://doi.org/10.1097/aog.0000000000004084.*
2. *Dungan, Jeffrey S., et al. "Noninvasive Prenatal Screening (NIPS) for Fetal Chromosome Abnormalities in a General-Risk Population: An Evidence-Based Clinical Guideline of the American College of Medical Genetics and Genomics (ACMG)." Genetics in Medicine, vol. 25, no. 2, 2023, p. 100336.*
3. *Gregg, Anthony R., et al. "Noninvasive Prenatal Screening for Fetal Aneuploidy, 2016 Update: A Position Statement of the American College of Medical Genetics and Genomics." Genetics in Medicine, vol. 18, no. 10, 2016, pp. 1056–1065.*

WHAT DOES **VERACITY** TEST FOR?

The conditions tested by VERACITY are relatively common in the population and can significantly affect the health, development, and quality of life of the affected individual.

Prenatal screening of these conditions can **improve prenatal clinical care** and facilitate making **informed decisions** early on.



TRISOMY
3 copies of a chromosome instead of 2

AUTOSOMAL ANEUPLOIDIES

A change in one of the chromosomal pairs 1-22

Down syndrome *(Trisomy 21)*
Edwards syndrome *(Trisomy 18)*
Patau syndrome *(Trisomy 13)*

Down, Edwards and Patau syndromes are the most common autosomal foetal aneuploidies. The incidence of these conditions **increases with maternal age**.

SEX CHROMOSOME ANEUPLOIDIES (SCAs)

A change in the 23rd chromosomal pair, which defines gender

Turner syndrome *(Monosomy X)*
Triple X syndrome *(Trisomy X)*
Klinefelter syndrome *(XXY)*
Jacobs syndrome *(XYY)*
XXYY syndrome

SCAs occur frequently in the population. They are not associated with maternal age, and as such they could potentially occur in pregnancies **irrespective of maternal age**.

MICRODELETIONS

A small part of a chromosome is missing


DiGeorge syndrome *(22q11.2)*
1p36 deletion syndrome *(1p36)*
Smith-Magenis syndrome *(17p11.2)*
Wolf-Hirschhorn syndrome *(4p16.3)*
Cri-du-Chat syndrome *(5p)**
Prader–Willi & Angelman syndromes *(15q11–q13)**

Apart from DiGeorge syndrome, which occurs frequently in the population, most microdeletions are rare. Microdeletions are **not associated with maternal age**, and as such have the same possibility of occurring in women **of all ages**.

**These microdeletions are currently tested at Medicover Genetics' laboratories in Cyprus and will be progressively introduced across additional laboratories within the Medicover Genetics network.*

HOW DOES **VERACITY** WORK?

During pregnancy, foetal DNA travels from the placenta to your bloodstream and circulates along with maternal DNA. The healthcare provider will collect a blood sample from the pregnant woman and send it to our laboratory for analysis. Our proprietary technology can differentiate foetal from maternal DNA and analyses it to screen for genetic disorders with high accuracy and precision. The results are sent to your healthcare provider in a few working days.



HOW SAFE IS VERACITY?

VERACITY is safe and does not pose any risk for the pregnant woman or her baby.

ARE THE CONDITIONS TESTED BY VERACITY ASSOCIATED WITH MATERNAL AGE?

The incidence of autosomal aneuploidies increases with maternal age. However, SCAs and microdeletions are not associated with maternal age so they can manifest at any maternal age group. In fact, medical gynaecological societies[1,2] recommend testing for:

- Trisomies 21, 18, 13
- SCAs
- 22q11.2 deletion

The VERACITY test is validated for singleton, twin, and vanishing twin pregnancies, including IVF pregnancies (using own eggs or donor eggs) and surrogacy.

WHAT ARE THE BENEFITS OF VERACITY NIPT OVER OTHER NIPTs?

The VERACITY NIPT screens for the specific genetic conditions recommended by medical guidelines, delivering **clear**, **reliable results** to your healthcare provider. Its powerful, targeted, high-resolution technology accurately detects even tiny genetic changes like microdeletions, avoiding common reliability issues found in other NIPTs.



BENEFITS OF **VERACITY**

EASY
Blood sample from pregnant woman


SAFE
Non-invasive sample collection

ACCURATE
>99% detection rate

FAST
Results in 4-7 working days from sample receipt

WHAT WILL THE **REPORT** SAY?

The VERACITY report will be sent to your healthcare provider. It will include a detailed explanation which will guide your healthcare provider on the best clinical management for you.



VERY LOW RISK

Reduced possibility of the foetus having one of the tested conditions

- In cases of very low risk results, your healthcare provider will continue with routine pregnancy clinical management.

VERY HIGH RISK

Increased possibility of the foetus having one of the tested conditions

- In cases of very high risk results, your healthcare provider will advise you on recommended next steps, such as genetic counseling and performing an invasive procedure to confirm whether the foetus has the genetic condition.

The percentage of the foetal DNA in the maternal circulation
Correct measurement of the foetal fraction is vital for accurate test results. Our laboratory accurately measures foetal fraction using novel software, and reports the foetal fraction percentage on the report as per recommendations from medical gynaecological societies[3].

A summary of the results and recommendations

Medicover Genetics offers upon request genetic counselling before and after VERACITY testing to help patients understand the purpose of testing, possible outcomes, and the implications of their results, supporting informed decisions throughout the process.

Compliance Disclaimer
VERACITY NIPT is a screening test, not a diagnostic test. Any very high risk result should be confirmed with invasive diagnostic testing, such as amniocentesis, before clinical decisions are made.
VERACITY is validated for singleton, twin, and vanishing twin pregnancies, including IVF (self egg, donor egg singleton, and surrogate) cases, but is not suitable for patients with recent transfusion, transplant, or malignancy.
Availability of specific test panels may vary by region depending on local legislation.
© Medicover Genetics Ltd. All rights reserved. Reproduction or modification of this content without authorisation is prohibited.

HOW CAN I TAKE THE **VERACITY** TEST?

Be at least 9 weeks pregnant

Ask your healthcare provider about **VERACITY**

Your healthcare provider will collect a blood sample from you



The samples will be sent to **Medicover Genetics**



The sample will be analyzed at **Medicover Genetics** laboratories

Results will be sent to your healthcare provider within 4-7 working days from sample receipt

MORE **QUESTIONS**?

If you have additional questions or concerns, please contact us at **info.genetics@medicover.com**

MEDICOVER
GENETICS

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

LRQA CERTIFIED ISO 13485 UKAS MEDICAL LABORATORIES 9561

CUSAS

ISO 9001

IQNET

Medicover Genetics Ltd
www.medicover-genetics.com

MKT-PRE-VC-PT-EN-V4